Anti-MYEOV monoclonal antibody

Pre-made anti-MYEOV monoclonal antibody(mab)-benchmark antibody for ELISA, affinity binding assay, drug discovery and mechanism of action (MOA) research

Target products collectionGo to MYEOV/MYEOV products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)


Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-IP1225-Ab-1/ GM-Tg-hg-IP1225-Ab-2Anti-Human MYEOV monoclonal antibodyHuman
GM-Tg-rg-IP1225-Ab-1/ GM-Tg-rg-IP1225-Ab-2Anti-Rat MYEOV monoclonal antibodyRat
GM-Tg-mg-IP1225-Ab-1/ GM-Tg-mg-IP1225-Ab-2Anti-Mouse MYEOV monoclonal antibodyMouse
GM-Tg-cynog-IP1225-Ab-1/ GM-Tg-cynog-IP1225-Ab-2Anti-Cynomolgus/ Rhesus macaque MYEOV monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-IP1225-Ab-1/ GM-Tg-felg-IP1225-Ab-2Anti-Feline MYEOV monoclonal antibodyFeline
GM-Tg-cang-IP1225-Ab-1/ GM-Tg-cang-IP1225-Ab-2Anti-Canine MYEOV monoclonal antibodyCanine
GM-Tg-bovg-IP1225-Ab-1/ GM-Tg-bovg-IP1225-Ab-2Anti-Bovine MYEOV monoclonal antibodyBovine
GM-Tg-equg-IP1225-Ab-1/ GM-Tg-equg-IP1225-Ab-2Anti-Equine MYEOV monoclonal antibodyEquine

Size: 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-IP1225-Ab-1/ GM-Tg-hg-IP1225-Ab-2; GM-Tg-rg-IP1225-Ab-1/ GM-Tg-rg-IP1225-Ab-2;
GM-Tg-mg-IP1225-Ab-1/ GM-Tg-mg-IP1225-Ab-2; GM-Tg-cynog-IP1225-Ab-1/ GM-Tg-cynog-IP1225-Ab-2;
GM-Tg-felg-IP1225-Ab-1/ GM-Tg-felg-IP1225-Ab-2; GM-Tg-cang-IP1225-Ab-1/ GM-Tg-cang-IP1225-Ab-2;
GM-Tg-bovg-IP1225-Ab-1/ GM-Tg-bovg-IP1225-Ab-2; GM-Tg-equg-IP1225-Ab-1/ GM-Tg-equg-IP1225-Ab-2
Products NameAnti-MYEOV monoclonal antibody
Formatmab
Target NameMYEOV
Protein Sub-locationIntrocelluar Protein
Category of antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)
IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by ELISA with recombinant soluble protein antigen. The potency in neutralizing, inhibiting or blocking of the target protein is not detected.
TagFc
Products descriptionPre-made anti-MYEOV monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenGM-Tg-g-IP1225-Ag-1Recombinant multi-species MYEOV/ OCIM protein


    Target information

    Target IDGM-IP1225
    Target NameMYEOV
    Gene ID26579,106993175
    Gene Symbol and SynonymsMYEOV,OCIM
    Uniprot AccessionQ96EZ4
    Uniprot Entry NameMYEOV_HUMAN
    Protein Sub-locationIntrocelluar Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000172927
    Target ClassificationN/A

    The target: MYEOV, gene name: MYEOV, also named as OCIM. .



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.